The public has wondered for some time why seemingly outrageous pricing for insulin and other critical medications has been tolerated. In a move that may bring some relief, the U.S. Food and Drug Administration (FDA) has amended its definition of a biologic product. While it may seem like a bureaucratic move with little relevancy, it is a needed transitional step resulting from … [Read more...]